Embecta Corp.

Embecta Corp. is a global medical device and medical supplies company dedicated to improving the lives of people living with diabetes. The company's mission is to develop and provide solutions that enhance diabetes management, building on a nearly 100-year legacy in insulin delivery. Headquartered in Parsippany, New Jersey, Embecta operates with a global footprint, serving customers in over 100 countries.

Embecta's core business revolves around insulin injection devices and related diabetes care supplies. Its product portfolio includes a variety of pen needles, insulin syringes, and safety injection devices. The company also offers a proprietary digital application designed to assist individuals with managing their diabetes. Embecta primarily distributes its products through wholesalers and distributors to retail and institutional channels, and also provides contract manufacturing services.

As of early 2026, Embecta's leadership includes Devdatt (Dev) Kurdikar as President, Chief Executive Officer, and Chairman of the Board, with Jake Elguicze serving as Chief Financial Officer. A notable recent development occurred in March 2026, when Embecta announced a definitive agreement to acquire Owen Mumford Holdings Limited. This acquisition of the UK-based medical device and drug-delivery technology manufacturer is intended to expand Embecta's drug-delivery portfolio and accelerate its strategic transformation into a broader medical supplies company.